Author [ref.] | Patients | No | Diagnosis | CIR | OS | LFS |
---|---|---|---|---|---|---|
Wang et al. [27], 2013 | HID-HSCT, retrospective | 756 | Leukemia | 15% (SR), 26% (HR) at 2 years | 68% (SR) at 3 years 49% (HR) at 3 years | |
Huang et al. [15], 2012 | HID-HSCT vs CT prospective | 58 vs 74 | AML-CR1 adults IR or HR | 12 vs 57%* | 7.5 vs 54.7%* at 4 years | 73.1 vs 44.2%* at 4 years |
Zhu et al. [35], 2013 | HSCT vs CT | 58 vs 58 | ETO(+) adults AML-CR1 | 22.1 vs 78.9% (HR)* 14.7 vs 5.3% (LR) | 71.6 vs 26.7% (HR)* 75.7 vs 100% (LR) | 61.7 vs 19.6% (HR)* 70.3 vs 94.7% (LR) |
Qin et al. [36], 2015 | HSCT vs CT | 57 vs 29 | In(16) adults AML-CR1 | 7.1 vs. 87.7% (poor MR)*; 0 vs. 26.9% (good MR); | 93.3 vs. 40.0%, (poor MR)*; 72.9 vs. 77.1% (good MR) | 86.7 vs. 12.3% (poor MR)* 72.9 vs. 73.1% (good MR) |
Yan et al. [82], 2014 | HID-HSCT vs CT | 79 vs 59 | SR-ALL-CR1 adults | 29.9 vs 66.3%* at 5 years | 70.4 vs 28%* at 5 years | 54.4 vs 23.9%* at 5 years |
Sun et al. [83], 2014 | HID-HSCT vs CT | 79 vs 104 | HR-ALL-CR1 adults | 18.7 vs 60.5%* at 3 years | 72.5 vs 26.6%*; at 3 years | 63.9 vs 21.1%* at 3 years |
Wang et al. [84], 2012 | HID-HSCT, T-ALL | 72 | T-ALL | 18.8% (CR1) 37.5% (non-CR1) | 54.8% (CR1) 12.5% (non-CR1) | |
Xu et al. [46], 2016 | HSCT | 52 | Pediatric T-ALL(HR) | 32.7% at 3 years | 55.5% at 3 years | 54.1% at 3 years |
Jiang et al. [85], 2011 | HSCT vs IM | 87 vs 45 | CML-AP adults | 81.2 vs 100% (LR) at 6 years 81.3 vs 61.3% (IR)* at 6 years 100 vs 17.7% (HR)* at 5years | 80.7 vs 80.9% (LR) at 6 years, 61.9 vs 47.1% (IR)* at 6 years 66.7 vs 9.3% (HR)* at 5 years | |
Xu et al. [52], 2016 | HSCT vs TKI2 | 60 vs 33 | CML-AP adults | 86.4 vs. 42.9%* at 5 years | 76.1 vs. 14.3%* at 5 years |